Apogee Therapeutics reports Q2 results (APGE:NASDAQ)
· seekingalpha.com
AbbVie to acquire Apogee Therapeutics for $135.11/share ($10.9B) after APGE posts Q2 net loss of $85.9M.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...